N0332 phase 2 trial of weekly irinotecan hydrochloride and docetaxel in refractory metastatic breast cancer

a North Central Cancer Treatment Group (NCCTG) Trial

W. W. Tan, D. W. Hillman, M. Salim, Donald W Northfelt, D. M. Anderson, P. J. Stella, R. Niedringhaus, A. M. Bernath, S. S. Gamini, F. Palmieri, E. A. Perez

Research output: Contribution to journalArticle

1 Citation (Scopus)
Original languageEnglish (US)
Number of pages1
JournalAnnals of oncology : official journal of the European Society for Medical Oncology
Volume29
Issue number10
DOIs
StatePublished - Oct 1 2018

Fingerprint

irinotecan
docetaxel
Manuscripts
Organized Financing
Breast Neoplasms
Neoplasms
corrigendum

ASJC Scopus subject areas

  • Hematology
  • Oncology

Cite this

N0332 phase 2 trial of weekly irinotecan hydrochloride and docetaxel in refractory metastatic breast cancer : a North Central Cancer Treatment Group (NCCTG) Trial. / Tan, W. W.; Hillman, D. W.; Salim, M.; Northfelt, Donald W; Anderson, D. M.; Stella, P. J.; Niedringhaus, R.; Bernath, A. M.; Gamini, S. S.; Palmieri, F.; Perez, E. A.

In: Annals of oncology : official journal of the European Society for Medical Oncology, Vol. 29, No. 10, 01.10.2018.

Research output: Contribution to journalArticle

Tan, W. W. ; Hillman, D. W. ; Salim, M. ; Northfelt, Donald W ; Anderson, D. M. ; Stella, P. J. ; Niedringhaus, R. ; Bernath, A. M. ; Gamini, S. S. ; Palmieri, F. ; Perez, E. A. / N0332 phase 2 trial of weekly irinotecan hydrochloride and docetaxel in refractory metastatic breast cancer : a North Central Cancer Treatment Group (NCCTG) Trial. In: Annals of oncology : official journal of the European Society for Medical Oncology. 2018 ; Vol. 29, No. 10.
@article{02b7dfe63f5c4253a714a6281ffce9af,
title = "N0332 phase 2 trial of weekly irinotecan hydrochloride and docetaxel in refractory metastatic breast cancer: a North Central Cancer Treatment Group (NCCTG) Trial",
author = "Tan, {W. W.} and Hillman, {D. W.} and M. Salim and Northfelt, {Donald W} and Anderson, {D. M.} and Stella, {P. J.} and R. Niedringhaus and Bernath, {A. M.} and Gamini, {S. S.} and F. Palmieri and Perez, {E. A.}",
year = "2018",
month = "10",
day = "1",
doi = "10.1093/annonc/mdx811",
language = "English (US)",
volume = "29",
journal = "Annals of Oncology",
issn = "0923-7534",
publisher = "Oxford University Press",
number = "10",

}

TY - JOUR

T1 - N0332 phase 2 trial of weekly irinotecan hydrochloride and docetaxel in refractory metastatic breast cancer

T2 - a North Central Cancer Treatment Group (NCCTG) Trial

AU - Tan, W. W.

AU - Hillman, D. W.

AU - Salim, M.

AU - Northfelt, Donald W

AU - Anderson, D. M.

AU - Stella, P. J.

AU - Niedringhaus, R.

AU - Bernath, A. M.

AU - Gamini, S. S.

AU - Palmieri, F.

AU - Perez, E. A.

PY - 2018/10/1

Y1 - 2018/10/1

UR - http://www.scopus.com/inward/record.url?scp=85045123937&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85045123937&partnerID=8YFLogxK

U2 - 10.1093/annonc/mdx811

DO - 10.1093/annonc/mdx811

M3 - Article

VL - 29

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

IS - 10

ER -